Advertisement

Tiziana Life Sciences Ltd TLSA

Set alert

Price alert · TLSA

All alert types
0.80 USD -0.10 -11.57%

At close · Oct 30

0.82 +0.02 +2.50%

After hours · Oct 30, 4:07 PM ET

Bid
0.80 × 1
Ask
0.82 × 7
0.79 Day range 0.9162
0.77 52-week range 1.92
YTD
-46.31%
1 year
-56.52%
Open
0.897
Prev close
0.9047
Mkt cap
101.81M
Vol
1.29M
Avg vol
773.63K
EPS
-0.21
P/E
0.00
Div yield
0.00%
More statistics
Low
0.79
High
0.9162
Forward P/E
-13.63
Beta
0.18
Short ratio
0.57
Inst. own
1.76%
Dividend
0.00
Ex-div date
Earnings
Aug 9, 2024
50-d avg
0.9492
200-d avg
0.86445
1y target
0.00

2Y chart

Chart tools
Interval

Signals (87)
NameDateAgo
SMA: BearishOct 19, 20261 week ago
MACD: Sell SignalOct 15, 20262 weeks ago
SMA: BullishSep 30, 20261 month ago
SMA: BearishSep 28, 20261 month ago
SMA: BullishSep 23, 20261 month ago
MACD: Buy SignalSep 23, 20261 month ago
RSI: OversoldSep 16, 20261 month ago
MACD: Sell SignalAug 31, 20262 months ago
SMA: BearishAug 26, 20262 months ago
SMA: BullishAug 20, 20262 months ago
SMA: BearishAug 19, 20262 months ago
SMA: BullishAug 14, 20262 months ago
MACD: Buy SignalAug 4, 20262 months ago
MACD: Sell SignalJul 16, 20263 months ago
SMA: BearishJul 14, 20263 months ago
SMA: BullishJul 13, 20263 months ago
MACD: Buy SignalJun 26, 20264 months ago
SMA: BearishJun 3, 20265 months ago
MACD: Sell SignalMay 27, 20265 months ago
MACD: Buy SignalMay 26, 20265 months ago
MACD: Sell SignalMay 22, 20265 months ago
MACD: Buy SignalMay 20, 20265 months ago
MACD: Sell SignalMay 18, 20265 months ago
RSI: OverboughtMay 8, 20265 months ago
SMA: BullishMay 1, 20266 months ago
SMA: BearishApr 17, 20266 months ago
MACD: Buy SignalApr 14, 20266 months ago
MACD: Sell SignalApr 13, 20266 months ago
MACD: Buy SignalApr 6, 20266 months ago
MACD: Sell SignalMar 27, 20267 months ago
MACD: Buy SignalMar 24, 20267 months ago
MACD: Sell SignalMar 11, 20267 months ago
SMA: BearishMar 3, 20268 months ago
SMA: BullishMar 2, 20268 months ago
MACD: Buy SignalFeb 26, 20268 months ago
MACD: Sell SignalFeb 2, 20269 months ago
SMA: BearishJan 28, 20269 months ago
SMA: BearishJan 28, 20269 months ago
SMA: BearishJan 22, 20269 months ago
SMA: BullishJan 21, 20269 months ago
SMA: BullishJan 21, 20269 months ago
SMA: BearishJan 20, 20269 months ago
SMA: BearishJan 20, 20269 months ago
SMA: BullishJan 16, 20269 months ago
SMA: BullishJan 16, 20269 months ago
MACD: Buy SignalJan 15, 20269 months ago
MACD: Sell SignalJan 12, 20269 months ago
MACD: Buy SignalJan 2, 202610 months ago
SMA: BearishDec 15, 202510 months ago
MACD: Sell SignalDec 15, 202510 months ago
MACD: Buy SignalNov 25, 202511 months ago
SMA: BearishNov 3, 202512 months ago
SMA: BullishOct 31, 20251 year ago
SMA: BearishOct 29, 20251 year ago
SMA: BullishOct 28, 20251 year ago
SMA: BearishOct 27, 20251 year ago
SMA: BullishOct 24, 20251 year ago
SMA: BearishOct 23, 20251 year ago
SMA: BullishOct 22, 20251 year ago
SMA: BearishOct 21, 20251 year ago
MACD: Sell SignalOct 16, 20251 year ago
SMA: BullishSep 24, 20251 year ago
MACD: Buy SignalSep 19, 20251 year ago
SMA: BearishSep 10, 20251 year ago
SMA: BullishSep 9, 20251 year ago
SMA: BullishAug 20, 20251 year ago
SMA: BearishAug 19, 20251 year ago
MACD: Sell SignalAug 13, 20251 year ago
RSI: OverboughtJul 25, 20251 year ago
MACD: Buy SignalJul 22, 20251 year ago
SMA: BullishJul 16, 20251 year ago
SMA: BearishJul 10, 20251 year ago
MACD: Sell SignalJul 1, 20251 year ago
MACD: Buy SignalJun 16, 20251 year ago
MACD: Sell SignalMay 16, 20251 year ago
MACD: Buy SignalApr 21, 20251 year ago
SMA: BearishApr 3, 20251 year ago
MACD: Sell SignalMar 19, 20251 year ago
RSI: OverboughtMar 5, 20251 year ago
RSI: OverboughtFeb 27, 20251 year ago
SMA: BullishFeb 14, 20251 year ago
MACD: Buy SignalFeb 11, 20251 year ago
MACD: Sell SignalJan 30, 20251 year ago
SMA: BearishJan 24, 20251 year ago
SMA: BullishJan 23, 20251 year ago
MACD: Buy SignalJan 10, 20251 year ago
RSI: OversoldDec 23, 20241 year ago

Key statistics

Market cap
70.76M
Enterprise value
78.46M
Trailing P/E
0.00
Forward P/E
-13.63
PEG ratio
0.00
Price / sales
0.00
Price / book
37.86
EPS (TTM)
-0.13
Beta
0.18
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-199.50K
Total cash
1.13M
Total debt
179.00K
Return on equity
-181.23%
Shares outstanding
103.82M
Short % of float
0.32%
50-day average
0.9492
200-day average
0.86445

Analyst view

Consensus: none

Price target (mean) 0.00

Next earnings

Aug 9, 2024

Expected Aug 9, 2024. Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
TLSA Revenue — annual 0
2016-FY 20162017-FY 20172018-FY 20182019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 2025
TLSA Net income — annual -18.43M
2016-FY 20162017-FY 20172018-FY 20182019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 2025
TLSA EPS — annual -0.16
2016-FY 20162017-FY 20172018-FY 20182019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 2025

Earnings

TLSA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Aug 9, 2024Mar 1, 20240.00———

Upgrades / downgrades

TLSA analyst upgrades and downgrades
DateFirmActionFromTo
Jun 13, 2022ThinkEquityinit—Buy

About Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.

Sector
Healthcare
Industry
Biotechnology
Country
United Kingdom

News

Your note

Sign in to keep a note on TLSA — it syncs with the Stock Master app.

Institution ownership

TLSA institution ownership
Holder% heldSharesValueReported
Sanctuary Advisors, LLC 0.86%907,613618.54KSep 29, 2024
Geode Capital Management, LLC0.21%218,681149.03KSep 29, 2024
HSBC Holdings PLC0.11%115,36578.62KSep 29, 2024
Morgan Stanley0.10%109,74774.79KSep 29, 2024
Citadel Advisors Llc0.10%104,29171.07KSep 29, 2024
Kovitz Investment Group Partners, Llc0.08%79,36554.09KSep 29, 2024

Fund ownership

TLSA fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index ETF0.15%162,797110.95KOct 30, 2024
Fidelity NASDAQ Composite Index Fund0.05%55,88438.08KOct 30, 2024
Advertisement